Alzheimer’s disease (AD) was first identified in 1901 by German psychiatrist Alois Alzheimer. Even though over a century has passed, scientists have not yet been able to find a cure for the disease. In an effort to slow down its progression, several pharmaceutical drugs have been developed and are frequently prescribed.
At Neuronix, we have taken a new approach to treating Alzheimer’s disease by developing the only medical device in the world that combines two treatment mechanisms. The first is known as Transcranial Magnetic Stimulation (TMS) and the second is Cognitive Training (CgT). While each treatment mechanism has been researched individually, we are the first company to merge the two. Our extensive clinical studies have confirmed that this combination yields a synergistic effect that results in cognitive, functional and behavioral improvements for individuals with mild to moderate AD. While unfortunately our technology does not cure the disease, it has been shown to help patients regain some of their lost abilities such as reading, painting or gardening. Treated patients have stated that they can better follow conversations and feel more oriented in their surroundings.
- Safe and Effective Treatment
- Measurable Cognitive and Functional Improvements
- Non-Invasive and Painless
- Minimal Side Effects
- An Adjunctive Therapy to Existing Medications
Treatment with the Neuronix neuroADTM Therapy System is very safe and completely non-invasive. The treatment course consists of one-hour sessions performed five times a week, for six weeks. Side effects or pain such as headaches, fatigue and neck pain, are mild and rare, and resolve themselves within several hours. Following each treatment you can immediately return to your daily activities.
MAGNETIC RESONANCE IMAGING
Prior to treatment, you will undergo a Magnetic Resonance Imaging (MRI) scan that will identify regions in your brain that have been affected by AD. Using the MRI scan, the Neuronix team marks the precise location of these brain regions and registers their spatial coordinates. These coordinates are then uploaded into the neuroADTM Therapy System.
Using a proprietary infrared optical Navigation Unit, the TMS applicator is placed against the scalp so that the selected brain region can be precisely stimulated. The applicator is made of a coil which emits a focused magnetic field that strengthens the signal transmission and chemical bonds between the neurons in the brain. This strengthening process is hypothesized to promote Long-term potentiation (LTP) – the primary cellular mechanism responsible for memory and cognitive functions.
Transcranial Magnetic Stimulation
TMS has been used in medical settings since 1985 and has an extremely high safety profile. It has been beneficial in the treatment of depression, obsessive-compulsive disorder (OCD), posttraumatic stress disorder, migraines and more.
You will be asked to perform cognitive exercises concurrently with the TMS stimulation. The exercises have been designed to correlate with the region of the brain being stimulated with TMS. For example, if the brain region responsible for judgement capabilities is being stimulated with TMS, then you will be asked to compare between two objects. The exercises are challenging, yet not frustrating, and the program adjusts itself to your precise level of comprehension.
The purpose of the cognitive training is to improve the functionality of the neuron connections that are being stimulated and reinforce the brain’s cognitive reserve, or the brain’s ability to function in the presence of brain pathology.
While TMS and Cognitive training have each been tested individually in various studies, neither have been shown to repeatedly yield long lasting or unequivocal results. The TMS alone has an effect that lasts only several minutes, and the cognitive training has not proven itself as effective in treating patients with AD. Neuronix has discovered that only by combining the technologies, measurable lasting improvements can be achieved. Click here to review our clinical evidence.
The long-term effect of treatment with the neuroADTM Therapy System varies from individual to individual, but small-scale clinical studies have shown that the effect may last between six months and two years.